Company intelligence / Profile preview

Jambo Technology

Hsinchu, Taiwan

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Jambo Technology is a clinical-stage biotechnology company focused on developing innovative drug delivery platforms for macromolecules. Based in Taiwan, the company utilizes its proprietary Jambo-Carrier technology to enable the oral administration of biologics that are typically limited to injections. Their lead programs include oral formulations of insulin and GLP-1 receptor agonists aimed at treating diabetes and obesity. By enhancing the bioavailability and stability of peptides in the digestive tract, Jambo Technology aims to revolutionize the treatment landscape for chronic metabolic conditions.

Therapeutic areas: Endocrinology
Modalities: PeptidesBiologicProtein
Industry: Biotech

Beyond the preview

Go deeper on Jambo Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jambo Technology.

Explore the full profile